The FDA's approval is based on results from the Phase III DESTINY-Breast09 trial, in which the combo showed a median 40.7-month progression-free survival.

Experts at SABCS said better prospective trials of ctDNA and more sensitive assays could bring ctDNA testing closer to the ...

Lunit will use two of its AI-based SCOPE platform to analyze immunohistochemistry slides and the tumor microenvironment.

Anavex had proposed restricting the drug's indication to patients with early Alzheimer's without mutations in the SIGMAR1 gene.

The firm will share updated data and new analyses from its Phase III trial with the agency, which issued a complete response ...

The agency said that although Akeega with prednisone improved outcomes in all patients with HRR mutations, the benefits were driven by those with BRCA2 mutations.

A large international analysis found no adverse effect of menopausal hormonal therapy among women with high genetic cancer risks.

NEW YORK – TransCode Therapeutics' microRNA-10b inhibitor TTX-MC138 will be included in a Phase II branch of the PRE-I-SPY trial, the company announced Thursday.

Black patients were less likely to receive PARP inhibitors, despite having BRCA1/2 testing and positivity rates comparable to White patients, and were at higher risk of death.

The financing comes as the FDA has lifted a clinical hold on the firm's MyPEAK-1 trial testing TN-201 in MYBPC3-associated hypertrophic cardiomyopathy.

The AI-driven platform identifies cell cycle deregulation and tumor immune microenvironment dynamics from biopsy images.

The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...